NSE: ZYDUSLIFE | BSE: 532321

Turnaround Potential

Download real time

1150.80 -8.20 (-0.71%)

New 52W High in past week

859.7K NSE+BSE Volume

NSE 10 Jul, 2026 3:57 PM (IST)

115,797.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

Dividend

Zydus Lifesciences has an upcoming dividend of ₹1.000 per share due on 24 Jul 2026 See details

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Search Inside the pdf :

Zydus Lifesciences Ltd.

25 May 2026

1150.80

-0.71%

Strong Execution Across US Specialty Pipeline and Diversified Businesses Supports Long-Term Growth

Accumulate: Zydus Lifesciences Ltd.

Recommendation Target

Deven Choksey

Zydus Lifesciences is increasingly positioning itself as a differentiated specialty-led healthcare company with multiple long-term growth drivers beyond traditional generics.

Zydus Lifesciences has gained 27.55% in the last 3 Months

Zydus Lifesciences Ltd.

20 May 2026

1150.80

-0.71%

DF/EM offset moderating US business

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus LifeSciences (ZYDUSLIF) delivered a better-than-expected financial performance in 4QFY26, with 9.5%/19%/11% beat on revenue/EBITDA/PAT.

Zydus Lifesciences has gained 28.60% in the last 6 Months

Zydus Lifesciences Ltd.

11 Feb 2026

1150.80

-0.71%

Zydus Lifesciences (ZYDUSLIF IN) Q3FY26 Result Update US sales hinges on timely high value launches Accumulate

Accumulate: Zydus Lifesciences Ltd.

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q3 EBITDA was largely in line with our estimates. We believe base business remains steady with mild erosion. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27E given sales erosion in some of key products and thereby expect flat EPS CAGR over FY25-28E. Mgmt have guided for 2-3 high value launches over...

Number of FII/FPI investors increased from 682 to 698 in Mar 2026 qtr.

Zydus Lifesciences Ltd.

10 Feb 2026, 12:00AM

1150.80

-0.71%

Operational beat; DF/NA/international markets drive earnings

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus Lifesciences (ZYDUSLIF) posted a better-than-expected operational performance in 3QFY26, with 8%/5% beat on revenue/EBITDA. Higher depreciation, interest costs and tax rate led to in-line earnings in 3Q.

Number of FII/FPI investors increased from 682 to 698 in Mar 2026 qtr.

Zydus Lifesciences Ltd.

07 Nov 2025

1150.80

-0.71%

Strong domestic and international growth offset US softness; margins moderated amid higher costs

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We remain constructive on Zydus Lifesciences given its improving business mix, continued progress on complex launches, and stable performance in India formulations.

Zydus Lifesciences L.. has an average target of 1051.20 from 5 brokers.

Zydus Lifesciences Ltd.

07 Nov 2025

1150.80

-0.71%

Zydus Lifesciences (ZYDUSLIF IN) Q2FY26 Result Update US...

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences has gained 27.55% in the last 3 Months

Zydus Lifesciences Ltd.

07 Nov 2025

1150.80

-0.71%

Limited visibility in US beyond current exclusivities

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) recent acquisitions in consumer wellness and medtech divisions helped it in driving a beat in Q2FY26 revenue though subdued margins of these businesses and lower revenue of gRevlimid dragged EBITDA margin (down 28bps YoY and 426bps QoQ).

Zydus Lifesciences L.. has an average target of 1051.20 from 5 brokers.

Zydus Lifesciences Ltd.

03 Sep 2025

1150.80

-0.71%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Zydus Lifesciences Ltd (Zydus) is one of India's leading, vertically integrated pharmaceutical companies. It operates across the value chain, from manufacturing finished dosages to active pharmaceutical ingredients, as well as animal healthcare and wellness products. Zydus' revenue increased 5.9% YoY to Rs. 6,574cr in Q1FY26 driven by 6.5% YoY...

Zydus Lifesciences has gained 27.55% in the last 3 Months

Zydus Lifesciences Ltd.

25 Aug 2025

1150.80

-0.71%

Q1FY26 performance stood stable amid slower traction in US offset by new product launches

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.

Zydus Lifesciences Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

13 Aug 2025

1150.80

-0.71%

Momentum may fizzle out on loss of exclusivities

Hold: Zydus Lifesciences Ltd.

ICICI Securities Limited

Zydus Lifesciences (Zydus)’s Q1FY26 print beat our expectations, though its revenue grew a mere 5.9% while EBITDA/PAT shrunk 3.3%/0.7% YoY. US biz sales were flat YoY.

Zydus Lifesciences L.. has an average target of 1051.20 from 5 brokers.

Is Cadila Healthcare Ltd. worth buying?

875 Votes:

Buy 81.94%

Sell 10.06%

Hold 8.0%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf